Platelet-Derived Growth Factor Compositions and Methods of Use Thereof
A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.
1 - 78 . (canceled)
79 . A method for promoting growth of bone, ligament, or cartilage of a mammal comprising administering to the mammal an implant material comprising a porous calcium phosphate having a solution of platelet-derived growth factor (PDGF) disposed therein, wherein PDGF has a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL, wherein the calcium phosphate comprises interconnected pores, the calcium phosphate consists of particles with having a size ranging from about 100 to about 5000 microns, and wherein the implant material promotes the growth of the bone, ligament, or cartilage.
80 . The method of claim 79 , wherein the PDGF has a concentration of about 0.3 mg/mL.
81 . The method of claim 79 , wherein the PDGF has a concentration of about 1.0 mg/mL.
82 . The method of claim 79 , wherein the calcium phosphate is selected from the group consisting of tricalcium phosphate, hydroxyapatite, poorly crystalline hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, octacalcium phosphate, and mixtures thereof.
83 . The method of claim 79 , wherein the calcium phosphate is tricalcium phosphate and the tricalcium phosphate is β-tricalcium phosphate (β-TCP).
84 . The method of claim 83 , wherein the β-TCP is in a particle form and the particles have a size in the range of about 100 to about 3000 m.
85 . The method of claim 84 , wherein the β-TCP particles have a size in the range of about 250 to about 2000 m.
86 . The method of claim 79 , wherein the implant material delivers the PDGF to the bone, ligament, or cartilage for at least 1 day following administration.
87 . The method of claim 79 , wherein the PDGF is released from the implant material upon administration at an average rate of less than or equal to 300 g/day.
88 . The method of claim 79 , wherein the PDGF is in a pharmaceutically acceptable liquid carrier.
89 . The method of claim 79 , wherein the PDGF is PDGF-AA, PDGF-BB, PDGF-CC, or PDGF-DD, or a combination thereof or a derivative thereof.
90 . The method of claim 79 , wherein the PDGF is recombinant human (rh) PDGF-BB.
91 . The method of claim 79 , wherein the concentration of PDGF is about 0.3 mg/mL.
92 . The method of claim 79 , wherein the concentration of PDGF is about 0.25 to about 5.0 mg/mL.
93 . The method of claim 79 , wherein the calcium phosphate is selected from the group consisting of tricalcium phosphate, hydroxyapatite, poorly crystalline hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, octacalcium phosphate and mixtures thereof.
94 . The method of claim 79 , wherein the calcium phosphate is tricalcium phosphate and the tricalcium phosphate is β-tricalcium phosphate (β-TCP).
95 . The method of claim 94 , wherein the β-TCP comprises particles having a size in the range of about 250 to about 2000 microns.
96 . The method of claim 79 , wherein the implant material further comprises collagen.